C. Tian - Biostat, Incyte Corp | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 11 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A First-in-human Phase I Study of the PD-1 Inhibitor, Retifanlimab (INCMGA00012), in Patients with Advanced Solid Tumors (POD1UM-101)

N. Lakhani,R. Cosman, U. Banerji,D. Rasco, M. Tomaszewska-Kiecana, E. Garralda,D. Kornacki, J. Li,C. Tian, N. Bourayou,J. Powderly

ESMO OPENno. 4 (2024)

引用0浏览0WOS引用

Open-label, Dose-Escalation FIGHT-101 Study of Pemigatinib Combined with Targeted Therapy, Chemotherapy, or Immunotherapy in Patients with Advanced Malignancies

M. Saleh,M. Barve,V. Subbiah,K.P. Papadopoulos,D. Morgensztern, N.B. Mettu,S. Roychowdhury,I. Spanggaard, M.L. Veronese,C. Tian,I.M. Silverman, M. Gutierrez

ESMO Openno. 7 (2024): 103625

引用0浏览0引用

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

M. Saleh,M. Barve,V. Subbiah,K.P. Papadopoulos,D. Morgensztern, N.B. Mettu,S. Roychowdhury,I. Spanggaard,M.L. Veronese,C. Tian,I.M. Silverman, M. Gutierrez

ESMO Open（2024）

引用0浏览0WOS引用

755P Retifanlimab in Patients with Recurrent Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dmmr) Endometrial Cancer: Final Results from the POD1UM-101 Study (cohort H)

D. Berton-Rigaud,P. Pautier,D. Lorusso,C. Gennigens,L. Gladieff,A. Kryzhanivska, J. Bowman,C. Tian,M. Cornfeld,T. Van Gorp

Annals of Oncology (2023): S517-S517

引用0浏览0引用

1146P Updated Results from POD1UM-201: A Phase II Study of Retifanlimab in Patients with Advanced or Metastatic Merkel Cell Carcinoma (MCC)

G. Grignani,P. Rutkowski,C. Lebbe,M. Guida,C. Gaudy Marqueste,F. G. M. De Braud,F. Spagnolo,M. Burgess,H. Montaudie,R. Depenni,F. Spada,J. Pulini,M. Cornfeld,C. Tian, S. Bhatia

Annals of oncology（2023）

引用0浏览0引用

FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies

V Subbiah, N O Iannotti,M Gutierrez,D C Smith,L Féliz, C F Lihou,C Tian,I M Silverman,T Ji,M Saleh

Annals of oncology : official journal of the European Society for Medical Oncology（2022）

引用66浏览0WOS引用

A Phase II Study of Retifanlimab (INCMGA00012) in Patients with Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

S. Rao,G. Anandappa,J. Capdevila,L. Dahan,L. Evesque,S. Kim,M. P. Saunders,D. C. Gilbert,L. H. Jensen,E. Samalin,K-L Spindler,S. Tamberi,A. Demols,M. G. Guren,D. Arnold,M. Fakih, T. Kayyal,M. Cornfeld,C. Tian, M. Catlett, M. Smith, J-P Spano

ESMO open（2022）

引用14浏览0WOS引用

P79.03 A Phase 3 Study of the PD-1 Inhibitor Retifanlimab (INCMGA00012) Plus Platinum-Based Chemotherapy in 1L Mnsclc: POD1UM-304

S. Lu,A. Chand,C. Vaz De Melo Sette,I. Bondarenko,H. Fang,S. Shankar,C. Tian,M. Munteanu,P. Ruff

Journal of thoracic oncologyno. 3 (2021): S646-S647

引用0浏览0引用

A Phase 3 Study Of The Pd-1 Inhibitor Retifanlimab (Incmga00012) Plus Platinum-Based Chemotherapy In 1l Mnsclc: Pod1um-304

S. Lu,A. Chand,C. Vaz De Melo Sette,I. Bondarenko,H. Fang,S. Shankar,C. Tian,M. Munteanu,P. Ruff

JOURNAL OF THORACIC ONCOLOGY（2021）

引用1浏览0引用

LBA42 POD1UM-202: Phase II Study of Retifanlimab in Patients (pts) with Squamous Carcinoma of the Anal Canal (SCAC) Who Progressed Following Platinum-Based Chemotherapy

S. Rao,J. Capdevila,D. Gilbert,S. Kim,L. Dahan, T. Kayyal,M. Fakih,A. Demols,L. H. Jensen,K-L. G. Spindler,D. Arnold,S. Tamberi,M. G. Guren,M. Cornfeld,M. Jones,C. Tian, M. Catlett,J-P. Spano

Annals of oncology（2020）

引用20浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn